287 related articles for article (PubMed ID: 30482746)
1. Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.
Miller AM; Bahmanof M; Zehn D; Cohen EEW; Schoenberger SP
Cancer Immunol Res; 2019 Jan; 7(1):40-49. PubMed ID: 30482746
[TBL] [Abstract][Full Text] [Related]
2. CD8
Gröschel C; Sasse A; Monecke S; Röhrborn C; Elsner L; Didié M; Reupke V; Bunt G; Lichtman AH; Toischer K; Zimmermann WH; Hasenfuß G; Dressel R
Front Immunol; 2018; 9():2665. PubMed ID: 30498501
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade.
Snook JP; Soedel AJ; Ekiz HA; O'Connell RM; Williams MA
Cancer Immunol Res; 2020 Apr; 8(4):506-517. PubMed ID: 32075800
[TBL] [Abstract][Full Text] [Related]
4. PTPN2 restrains CD8⁺ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice.
Wiede F; Ziegler A; Zehn D; Tiganis T
J Autoimmun; 2014 Sep; 53():105-14. PubMed ID: 24997008
[TBL] [Abstract][Full Text] [Related]
5. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.
Keir ME; Freeman GJ; Sharpe AH
J Immunol; 2007 Oct; 179(8):5064-70. PubMed ID: 17911591
[TBL] [Abstract][Full Text] [Related]
6. Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity.
Weinhold M; Sommermeyer D; Uckert W; Blankenstein T
J Immunol; 2007 Oct; 179(8):5534-42. PubMed ID: 17911640
[TBL] [Abstract][Full Text] [Related]
7. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
8. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
10. Induction of GVHD-like skin disease by passively transferred CD8(+) T-cell receptor transgenic T cells into keratin 14-ovalbumin transgenic mice.
Shibaki A; Sato A; Vogel JC; Miyagawa F; Katz SI
J Invest Dermatol; 2004 Jul; 123(1):109-15. PubMed ID: 15191550
[TBL] [Abstract][Full Text] [Related]
11. Cross-presentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity.
Kurts C; Heath WR; Carbone FR; Kosaka H; Miller JF
Novartis Found Symp; 1998; 215():172-81; discussion 181-90. PubMed ID: 9760579
[TBL] [Abstract][Full Text] [Related]
12. Acquired pMHC I complexes greatly enhance CD4(+) Th cell's stimulatory effect on CD8(+) T cell-mediated diabetes in transgenic RIP-mOVA mice.
Ahmed KA; Xie Y; Zhang X; Xiang J
Cell Mol Immunol; 2008 Dec; 5(6):407-15. PubMed ID: 19118506
[TBL] [Abstract][Full Text] [Related]
13. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
14. Intestinal epithelial antigen induces mucosal CD8 T cell tolerance, activation, and inflammatory response.
Liu Z; Lefrançois L
J Immunol; 2004 Oct; 173(7):4324-30. PubMed ID: 15383561
[TBL] [Abstract][Full Text] [Related]
15. The use of mouse models to better understand mechanisms of autoimmunity and tolerance.
Miyagawa F; Gutermuth J; Zhang H; Katz SI
J Autoimmun; 2010 Nov; 35(3):192-8. PubMed ID: 20655706
[TBL] [Abstract][Full Text] [Related]
16. Urinary bladder epithelium antigen induces CD8+ T cell tolerance, activation, and autoimmune response.
Liu W; Evanoff DP; Chen X; Luo Y
J Immunol; 2007 Jan; 178(1):539-46. PubMed ID: 17182594
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
18. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
19. Constitutive class I-restricted exogenous presentation of self antigens in vivo.
Kurts C; Heath WR; Carbone FR; Allison J; Miller JF; Kosaka H
J Exp Med; 1996 Sep; 184(3):923-30. PubMed ID: 9064352
[TBL] [Abstract][Full Text] [Related]
20. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
Goldberg J; Shrikant P; Mescher MF
J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
